Navigation Links
Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Date:9/16/2009

ds and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding potential FDA marketing approval for KRYSTEXXA(TM) (pegloticase), whether any further clinical trials will be required, the actions that may be required of Savient by the FDA in connection with the BLA, the reversion to and revalidation of the Phase 3 manufacturing process, the timing of a resubmission to the FDA in response to the complete response letter and the efficacy and safety of KRYSTEXXA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data, our current understanding of the complete response letter and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may raise further issues regarding the BLA for KRYSTEXXA or require that we conduct additional clinical trials, our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
2. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
3. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
4. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
5. Savient Announces Appointment of David Gionco as Chief Financial Officer
6. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
7. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Savient Submits Biologics License Application (BLA) for pegloticase
9. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
10. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
11. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... MARIETTA, Ga. , Aug. 3, 2015  MiMedx ... medicine company utilizing human amniotic tissue and patent-protected processes ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... will present at the 35 th Annual Canaccord|Genuity ...  Parker H. "Pete" Petit, Chairman and CEO, William ...
(Date:8/3/2015)... WESTWOOD, Mass. , Aug. 3, 2015  Merck ... company for innovative and top-quality high-tech products in the ... together with the US-based company Nano-C, their development and ... field of organic photovoltaics (OPV). Merck KGaA, Darmstadt, ... participate in the growing OPV sector. Novel ...
(Date:8/3/2015)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), the ... diseases, today announced that it will host its First ... Thursday, August 13, 2015 at 4:30 p.m. Eastern Time. ... release of fiscal 2016 first quarter results.  A recorded ... hours after the call at the Investor Relations portion ...
(Date:8/3/2015)... , Aug. 3, 2015   Intrexon Corporation ... first half and second quarter 2015 financial results after ... 2015.  The Company will host a conference call at ... a general business update. The conference call ... 1-412-902-4262 (International), and asking to join the "Intrexon Corporation ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2
... Eindhoven University of Technology (TU/e) has appointed prof. dr. Stuart ... professor at Stanford University and an IBM Fellow of the ... he was awarded an honorary doctorate by TU/e. Parkin is ... is the first ,distinguished professor, of TU/e, an international top ...
... ANGELES, Oct. 20 Humanitarian, Dr. Gary Michelson,is ... animals,",says Aimee Gilbreath, Executive Director of Found Animals ... 501(c)3., Found Animals and its strategic partner ... announced the launch of The Michelson Prize in,Reproductive ...
... directors,of Eli Lilly and Company (NYSE: LLY ) today ... a share on outstanding common stock. This,is the same dividend ... and,brings the total annual dividend for 2008 to $1.88 per ... shareholders of record at,the close of business on November 14, ...
Cached Biology Technology:Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 2Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 3Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 4
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... athletic performance can lead to diabetes, reports a study published ... , The study reports the case of a 36 year ... , He had lost 40 kg in 12 months, ... appetite. , He admitted to using anabolic steroids for ...
... develop high levels of genetic diversity and acquire mutations ... producing a vaccine. David Nickle et al present here ... the diversity of HIV or other variable pathogens. , ... in the strains of the virus by describing the ...
... University School of Medicine has helped confirm the reliability ... ushering in the long-promised era of personalized medicine based ... one of the five sites that helped determine that ... risk of developing cirrhosis from chronic hepatitis C infection. ...
Cached Biology News:New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3
Gamma delta T Lymphocytes Purified Anti-Porcine clone MAC320, Isotype Rat IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Request Info...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
... Xylene Resistant (X/R) Red System consists ... Red Activator and X/R Red Buffer. ... alkaline phosphatase to produce red staining ... ,Kit Contains:, , Buffer, 100 mL ...
Biology Products: